Nakayama, Kazuhiro http://orcid.org/0000-0002-2655-5472
Osaka, Wakako
Matsubara, Nobuaki
Takeuchi, Tsutomu
Toyoda, Mayumi
Ohtake, Noriyuki
Uemura, Hiroji
Funding for this research was provided by:
Janssen Pharmaceutical K.K.
Article History
Received: 10 February 2020
Accepted: 30 November 2020
First Online: 14 December 2020
Ethics approval and consent to participate
: This study was approved by The Ethics Review Committee of The Jikei University School of Medicine (approved number: 30–194(9215)) and conducted following the guidelines of the Declaration of Helsinki. Before conducting the questionnaire, we explained in writing to both the patient and physician groups that their answers would be anonymized so that no individual could be identified, that answers would be used only as statistical survey results and that the questionnaire was voluntary. Since participation was anonymous and voluntary, consent was implicitly obtained by completing the questionnaire. Before issuing the questionnaire, we added a postscript disclaiming that the questionnaire for the patient group included questions about “physical condition/symptoms.”
: Not applicable.
: This study was funded by Janssen Pharmaceutical K.K. KN declares no conflicts of interest. WO declares no conflicts of interest. NM received funding from Janssen Pharmaceutical K.K., Sanofi, Taiho Pharmaceutical, AstraZeneca and Bayer Yakuhin during the conduct of this study. TT declares no conflicts of interest. ON is a full-time employee of Janssen Pharmaceutical K.K. MT is a full-time employee of Janssen Pharmaceutical K.K. HU received funding from Janssen Pharmaceutical K.K., Bayer Yakuhin, Taiho Pharmaceutical, Astellas Pharma and Pfizer.